688302 海创药业
已收盘 03-28 15:00:00
资讯
新帖
简况
和讯个股快报：2023年03月27日 海创药业-U （688302），股价出现向上跳空缺口
自选股智能写手 · 03-27 09:27
和讯个股快报：2023年03月27日 海创药业-U （688302），股价出现向上跳空缺口
西南证券：给予海创药业买入评级，目标价位77.7元
证券之星 · 03-26 10:45
西南证券：给予海创药业买入评级，目标价位77.7元
公告精选︱晶澳科技拟斥资128.42亿元扩产；格力地产拟以89.78亿元收购免税集团100%股权
格隆汇 · 03-22
公告精选︱晶澳科技拟斥资128.42亿元扩产；格力地产拟以89.78亿元收购免税集团100%股权
海创药业：德恩鲁胺（HC-1119软胶囊）新药上市申请获得受理
财通社 · 03-22
海创药业：德恩鲁胺（HC-1119软胶囊）新药上市申请获得受理
海创药业（688302）3月20日主力资金净卖出1195.72万元
证券之星 · 03-21
海创药业（688302）3月20日主力资金净卖出1195.72万元
海创药业-U盘中异动 股价振幅达6.77% 跌6.87% 报58.48元
自选股智能写手 · 03-20
海创药业-U盘中异动 股价振幅达6.77% 跌6.87% 报58.48元
生物医药板块跌0.97% 海创药业涨7.79%居首
中国经济网 · 03-14
生物医药板块跌0.97% 海创药业涨7.79%居首
海创药业（688302）3月9日主力资金净卖出194.04万元
证券之星 · 03-10
海创药业（688302）3月9日主力资金净卖出194.04万元
海创药业（688302）3月7日主力资金净买入96.50万元
证券之星 · 03-08
海创药业（688302）3月7日主力资金净买入96.50万元
海创药业创始人、董事长陈元伟：加大前沿生物医药技术平台建设 加速国产创新药成果转化
每日经济新闻 · 03-02
海创药业创始人、董事长陈元伟：加大前沿生物医药技术平台建设 加速国产创新药成果转化
海创药业：公司自研PROTAC前列腺癌口服药物HP518目前正在按计划顺利推进剂量爬坡试验
界面 · 02-28
海创药业：公司自研PROTAC前列腺癌口服药物HP518目前正在按计划顺利推进剂量爬坡试验
海创药业2022年度亏损3.02亿同比亏损减少 公司研发的多个创新药物项目持续稳步推进中
挖贝网 · 02-27
海创药业2022年度亏损3.02亿同比亏损减少 公司研发的多个创新药物项目持续稳步推进中
海创药业(688302.SH)2022年度净亏损3.02亿元
智通财经 · 02-27
海创药业(688302.SH)2022年度净亏损3.02亿元
海创药业（688302）2月24日主力资金净买入141.81万元
证券之星 · 02-25
海创药业（688302）2月24日主力资金净买入141.81万元
海创药业（688302）2月22日主力资金净卖出265.33万元
证券之星 · 02-23
海创药业（688302）2月22日主力资金净卖出265.33万元
生物医药板块涨0.36% 海创药业涨8.19%居首
中国经济网 · 02-22
生物医药板块涨0.36% 海创药业涨8.19%居首
海创药业（688302）2月16日主力资金净卖出54.19万元
证券之星 · 02-17
海创药业（688302）2月16日主力资金净卖出54.19万元
医药行业：痛风临床需求迅猛崛起 降尿酸创新药方兴未艾
光大证券 · 02-14
医药行业：痛风临床需求迅猛崛起 降尿酸创新药方兴未艾
海创药业多个在研项目临床试验申请获受理 近期机构密集调研
每日经济新闻 · 02-10
海创药业多个在研项目临床试验申请获受理 近期机构密集调研
海创药业HP530S片拟用于实体瘤临床试验申请获受理
中国证券网 · 02-10
海创药业HP530S片拟用于实体瘤临床试验申请获受理
加载更多
公司概况
公司名称：
海创药业股份有限公司
所属行业：
医药制造业
上市日期：
2022-04-12
主营业务：
海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台，以开发具有重大临床需求的Best-in-class（同类最佳）、First-in-class（国际首创）药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局，重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台，形成了较强的研发优势和丰富的技术储备。
发行价格：
42.92
{"stockData":{"symbol":"688302","market":"SH","secType":"STK","nameCN":"海创药业","latestPrice":55.24,"timestamp":1679986800000,"preClose":56.81,"halted":0,"volume":707232,"delay":0,"floatShares":23769600,"shares":99015600,"eps":-3.2201,"marketStatus":"已收盘","marketStatusCode":5,"change":-1.57,"latestTime":"03-28 15:00:00","open":56.88,"high":56.88,"low":55,"amount":39296100,"amplitude":0.0331,"askPrice":55.41,"askSize":2,"bidPrice":55.24,"bidSize":5,"shortable":0,"etf":0,"ttmEps":-3.2201,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1680053400000},"adr":0,"adjPreClose":56.81,"symbolType":"stock_kcb","highLimit":62.49,"lowLimit":51.13,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":99015598,"pbRate":3.34,"roa":"--","roe":"--","epsLYR":-4.12,"committee":-0.411765,"marketValue":5470000000,"floatMarketCap":1313000000,"peRate":-17.154747,"changeRate":-0.0276,"turnoverRate":0.0298,"status":1,"afterMarket":{"amount":0,"volume":0,"close":55.24,"buyVolume":0,"sellVolume":0,"time":1679988837245,"indexStatus":"已收盘 03-28 15:30:00","preClose":56.81}},"requestUrl":"/m/hq/s/688302","defaultTab":"news","newsList":[{"id":"2322493141","title":"和讯个股快报：2023年03月27日 海创药业-U （688302），股价出现向上跳空缺口","url":"https://stock-news.laohu8.com/highlight/detail?id=2322493141","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2322493141?lang=zh_CN&edition=full","pubTime":"2023-03-27 09:27","pubTimestamp":1679880424,"startTime":"0","endTime":"0","summary":"受板块利好消息影响，该股快速拉升，出现向上跳空缺口，说明多方力量聚集，主力资金做多意愿明显。截至发稿，该股报57.5元/股，成交量0.001万手，换手率0%，振幅0%，量比0.13。（以上内容为自选股智能机器写手差分机完成，仅作为用户看盘参考，不能作为操作依据。）风险提示：以上内容仅作为作者或者嘉宾的观点，不代表和讯的任何立场，不构成与和讯相关的任何投资建议。在作出任何投资决定前，投资者应根据自身情况考虑投资产品相关的风险因素，并于需要时咨询专业投资顾问意见。和讯竭力但不能证实上述内容的真实性、准确性和原创性，对此和讯不做任何保证和承诺。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303270929478271164a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303270929478271164a&s=b","is_publish_highlight":false},{"id":"2322809264","title":"西南证券：给予海创药业买入评级，目标价位77.7元","url":"https://stock-news.laohu8.com/highlight/detail?id=2322809264","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2322809264?lang=zh_CN&edition=full","pubTime":"2023-03-26 10:45","pubTimestamp":1679798713,"startTime":"0","endTime":"0","summary":"西南证券股份有限公司杜向阳近期对海创药业进行研究并发布了研究报告《德恩鲁胺NDA获受理，未来可期》，本报告对海创药业给出买入评级，认为其目标价位为77.70元，当前股价为56.29元，预期上涨幅度为38.04%。考虑海创药业研发实力强劲，氘代和PROTAC技术平台实力出众，首款创新药德恩鲁胺NDA已获受理，维持“买入”评级。该股最近90天内共有2家机构给出评级，买入评级2家；过去90天内机构目标均价为77.7。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032600000080.shtml","is_publish_highlight":false},{"id":"2321993306","title":"公告精选︱晶澳科技拟斥资128.42亿元扩产；格力地产拟以89.78亿元收购免税集团100%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2321993306","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2321993306?lang=zh_CN&edition=full","pubTime":"2023-03-22 23:54","pubTimestamp":1679500462,"startTime":"0","endTime":"0","summary":"景嘉微(300474.SZ)：大基金拟减持不超2%股份；安集科技(688019.SH)：国家集成电路基金拟减持不超2.5%股份","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/111.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/588381","is_publish_highlight":false},{"id":"2321959859","title":"海创药业：德恩鲁胺（HC-1119软胶囊）新药上市申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2321959859","media":"财通社","top":-1,"share":"https://www.laohu8.com/m/news/2321959859?lang=zh_CN&edition=full","pubTime":"2023-03-22 17:52","pubTimestamp":1679478720,"startTime":"0","endTime":"0","summary":"【海创药业：德恩鲁胺（HC-1119软胶囊）新药上市申请获得受理】海创药业公告，德恩鲁胺（HC-1119软胶囊）新药上市申请获得受理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230322175241841cc57b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230322175241841cc57b&s=b","is_publish_highlight":false},{"id":"2321664711","title":"海创药业（688302）3月20日主力资金净卖出1195.72万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2321664711","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2321664711?lang=zh_CN&edition=full","pubTime":"2023-03-21 07:51","pubTimestamp":1679356314,"startTime":"0","endTime":"0","summary":"截至2023年3月20日收盘，海创药业报收于58.7元，下跌6.68%，换手率6.62%，成交量1.57万手，成交额9418.36万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入431.04万元，融资偿还478.78万元，融资净偿还47.74万元。根据近五年财报数据，证券之星估值分析工具显示，海创药业行业内竞争力的护城河一般，盈利能力较差，营收成长性较差。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023032100009898.shtml","is_publish_highlight":false},{"id":"2320576296","title":"海创药业-U盘中异动 股价振幅达6.77% 跌6.87% 报58.48元","url":"https://stock-news.laohu8.com/highlight/detail?id=2320576296","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2320576296?lang=zh_CN&edition=full","pubTime":"2023-03-20 10:12","pubTimestamp":1679278320,"startTime":"0","endTime":"0","summary":"2023年03月20日10时10分，海创药业-U股票出现波动，股价大幅跳水6.87%。截至发稿，该股报58.48元/股，成交量0.519万手，换手率2.19%，振幅6.77%。资金方面，该股资金流入1202.55万元，流出2069.76万元。海创药业-U所在的生物制品行业中，整体跌幅为-1.75%%。其相关个股中，沃森生物、义翘神州、毕得医药涨幅较大， 振幅较大的相关个股有海创药业-U、益方生物-U、首药控股-U，振幅分别为6.93%、6.54%、6.21%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230320101359826d466e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230320101359826d466e&s=b","is_publish_highlight":false},{"id":"2319074553","title":"生物医药板块跌0.97% 海创药业涨7.79%居首","url":"https://stock-news.laohu8.com/highlight/detail?id=2319074553","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2319074553?lang=zh_CN&edition=full","pubTime":"2023-03-14 17:11","pubTimestamp":1678785060,"startTime":"0","endTime":"0","summary":"中国经济网北京3月14日讯 今日，生物医药板块整体跌幅0.97%，其中45只股票上涨，2只股票平盘，129只股票下跌。数据显示，截至今日，生物医药板块近一周涨幅-1.37%，近一月涨幅-3.80%，近一季涨幅4.08%。其中，海创药业、荣昌生物、凯因科技、新莱应材、皓元医药位列板块涨幅前五位，涨幅分别为7.79%、6.67%、5.80%、5.38%、5.10%。万泽股份、亨迪药业、*ST辅仁、*ST吉药、雪榕生物位列涨幅榜后五位，涨幅分别为-6.93%、-6.60%、-5.26%、-5.14%、-5.06%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303141714528419614b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303141714528419614b&s=b","is_publish_highlight":false},{"id":"2318241600","title":"海创药业（688302）3月9日主力资金净卖出194.04万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2318241600","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2318241600?lang=zh_CN&edition=full","pubTime":"2023-03-10 07:51","pubTimestamp":1678405868,"startTime":"0","endTime":"0","summary":"截至2023年3月9日收盘，海创药业报收于59.45元，下跌2.28%，换手率1.61%，成交量3823.0手，成交额2288.99万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入137.22万元，融资偿还245.65万元，融资净偿还108.42万元。根据近五年财报数据，证券之星估值分析工具显示，海创药业行业内竞争力的护城河一般，盈利能力较差，营收成长性较差。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023031000002259.shtml","is_publish_highlight":false},{"id":"2317044184","title":"海创药业（688302）3月7日主力资金净买入96.50万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2317044184","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2317044184?lang=zh_CN&edition=full","pubTime":"2023-03-08 07:43","pubTimestamp":1678232625,"startTime":"0","endTime":"0","summary":"截至2023年3月7日收盘，海创药业报收于59.01元，上涨0.58%，换手率4.39%，成交量1.04万手，成交额6253.28万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入198.44万元，融资偿还360.22万元，融资净偿还161.77万元。根据近五年财报数据，证券之星估值分析工具显示，海创药业行业内竞争力的护城河一般，盈利能力较差，营收成长性较差。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023030800002563.shtml","is_publish_highlight":false},{"id":"2316495173","title":"海创药业创始人、董事长陈元伟：加大前沿生物医药技术平台建设 加速国产创新药成果转化","url":"https://stock-news.laohu8.com/highlight/detail?id=2316495173","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2316495173?lang=zh_CN&edition=full","pubTime":"2023-03-02 22:54","pubTimestamp":1677768843,"startTime":"0","endTime":"0","summary":"鼓励创新药企业夯实生物医药新型技术平台基础；以国家重大新药创制专项等为牵引，对能解决临床痛点的国产创新药研究给予成果商业转化支持；优化医保策略、鼓励社会资本投入，以可持续的方式提高优质国产创新药的可及性和可负担性。每日经济新闻","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303022256138265150d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202303022256138265150d&s=b","is_publish_highlight":false},{"id":"2314521243","title":"海创药业：公司自研PROTAC前列腺癌口服药物HP518目前正在按计划顺利推进剂量爬坡试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2314521243","media":"界面","top":-1,"share":"https://www.laohu8.com/m/news/2314521243?lang=zh_CN&edition=full","pubTime":"2023-02-28 16:43","pubTimestamp":1677573792,"startTime":"0","endTime":"0","summary":"海创药业近期在接受调研时表示，公司自主研发的PROTAC前列腺癌口服药物HP518，已于2021年10月获准在澳大利亚开展临床I期试验，并于2022年1月实现首例患者入组，目前正在按计划顺利推进剂量爬坡试验。2023年1月，HP518临床试验申请已获得美国FDA的正式批准。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023022816431282b9186b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023022816431282b9186b&s=b","is_publish_highlight":false},{"id":"2314656339","title":"海创药业2022年度亏损3.02亿同比亏损减少 公司研发的多个创新药物项目持续稳步推进中","url":"https://stock-news.laohu8.com/highlight/detail?id=2314656339","media":"挖贝网","top":-1,"share":"https://www.laohu8.com/m/news/2314656339?lang=zh_CN&edition=full","pubTime":"2023-02-27 22:43","pubTimestamp":1677509006,"startTime":"0","endTime":"0","summary":"挖贝网2月27日，海创药业 发布2022年度业绩快报，公告显示，2022年度营业总收入为165.08万元；归属于母公司股东的净利润为30,151.49万元，较上年同期亏损减少。报告期内公司研发的多个创新药物项目持续稳步推进中，处于不同临床试验研究阶段，研发支出持续投入，2022年研发费用25,136.74万元，同比减少5.12%，公司2022年度仍未实现盈利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202302272246208263148b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202302272246208263148b&s=b","is_publish_highlight":false},{"id":"2314342245","title":"海创药业(688302.SH)2022年度净亏损3.02亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2314342245","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2314342245?lang=zh_CN&edition=full","pubTime":"2023-02-27 18:15","pubTimestamp":1677492954,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海创药业(688302.SH)发布2022年度业绩快报，公司实现营业收入165.08万元，上年同期无营业收入;归属于母公司所有者的净亏损3.02亿元，同比减亏466.50万元;归属于母公司所有者的扣除非经常性损益的净亏损3.4亿元，同比减亏543.17万元。报告期内公司研发的多个创新药物项目持续稳步推进中，处于不同临床试验研究阶段，研发支出持续投入，2022年研发费用2.514亿元，同比减少5.12%，公司2022年度仍未实现盈利。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/883334.html","is_publish_highlight":false},{"id":"2314337091","title":"海创药业（688302）2月24日主力资金净买入141.81万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2314337091","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2314337091?lang=zh_CN&edition=full","pubTime":"2023-02-25 07:59","pubTimestamp":1677283197,"startTime":"0","endTime":"0","summary":"截至2023年2月24日收盘，海创药业报收于56.0元，下跌5.08%，换手率5.13%，成交量1.22万手，成交额6958.82万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入415.25万元，融资偿还347.15万元，融资净买入68.11万元。根据近五年财报数据，证券之星估值分析工具显示，海创药业行业内竞争力的护城河一般，盈利能力较差，营收成长性较差。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023022500002539.shtml","is_publish_highlight":false},{"id":"2313003744","title":"海创药业（688302）2月22日主力资金净卖出265.33万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2313003744","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2313003744?lang=zh_CN&edition=full","pubTime":"2023-02-23 07:51","pubTimestamp":1677109869,"startTime":"0","endTime":"0","summary":"截至2023年2月22日收盘，海创药业报收于58.15元，上涨8.19%，换手率4.78%，成交量1.14万手，成交额6440.7万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入336.59万元，融资偿还560.24万元，融资净偿还223.65万元。根据近五年财报数据，证券之星估值分析工具显示，海创药业行业内竞争力的护城河一般，盈利能力较差，营收成长性较差。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023022300001649.shtml","is_publish_highlight":false},{"id":"2313015867","title":"生物医药板块涨0.36% 海创药业涨8.19%居首","url":"https://stock-news.laohu8.com/highlight/detail?id=2313015867","media":"中国经济网","top":-1,"share":"https://www.laohu8.com/m/news/2313015867?lang=zh_CN&edition=full","pubTime":"2023-02-22 16:20","pubTimestamp":1677054000,"startTime":"0","endTime":"0","summary":"中国经济网北京2月22日讯 今日，生物医药板块整体涨幅0.36%，其中99只股票上涨，9只股票平盘，67只股票下跌。数据显示，截至今日，生物医药板块近一周涨幅0.44%，近一月涨幅3.19%，近一季涨幅8.42%。其中，海创药业、西藏药业、司太立、毕得医药、亨迪药业位列板块涨幅前五位，涨幅分别为8.19%、7.79%、7.31%、6.22%、5.98%。奥联电子、科恒股份、君实生物、皓元医药、普莱柯位列涨幅榜后五位，涨幅分别为-12.39%、-8.86%、-2.92%、-2.45%、-2.17%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202302221624138411a349&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202302221624138411a349&s=b","is_publish_highlight":false},{"id":"2312547107","title":"海创药业（688302）2月16日主力资金净卖出54.19万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2312547107","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2312547107?lang=zh_CN&edition=full","pubTime":"2023-02-17 07:51","pubTimestamp":1676591509,"startTime":"0","endTime":"0","summary":"截至2023年2月16日收盘，海创药业报收于53.53元，下跌6.15%，换手率3.88%，成交量9221.79手，成交额5079.71万元。近5日资金流向一览见下表：海创药业融资融券信息显示，融资方面，当日融资买入398.8万元，融资偿还410.93万元，融资净偿还12.13万元。根据近五年财报数据，证券之星估值分析工具显示，海创药业行业内竞争力的护城河一般，盈利能力较差，营收成长性较差。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2023021700001460.shtml","is_publish_highlight":false},{"id":"2311941181","title":"医药行业：痛风临床需求迅猛崛起 降尿酸创新药方兴未艾","url":"https://stock-news.laohu8.com/highlight/detail?id=2311941181","media":"光大证券","top":-1,"share":"https://www.laohu8.com/m/news/2311941181?lang=zh_CN&edition=full","pubTime":"2023-02-14 08:23","pubTimestamp":1676334180,"startTime":"0","endTime":"0","summary":"临床上患者仍然需要更加安全有效的治疗药物来实现长期控制尿酸水平的目标。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230214082644840e41a0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230214082644840e41a0&s=b","is_publish_highlight":false},{"id":"2310981643","title":"海创药业多个在研项目临床试验申请获受理 近期机构密集调研","url":"https://stock-news.laohu8.com/highlight/detail?id=2310981643","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2310981643?lang=zh_CN&edition=full","pubTime":"2023-02-10 18:05","pubTimestamp":1676023525,"startTime":"0","endTime":"0","summary":"今年2月以来，海创药业已经先后公布了PROTAC药物HP518临床试验申请获FDA批准、HP501缓释片和HP530S片药物临床试验申请获得受理的公告。此次获受理的临床试验申请是与黄嘌呤氧化酶抑制剂联合用于原发性高尿酸血症的长期治疗。海创药业近期在研项目进展披露较密集，公司也迎来多家机构调研。但截至目前，海创药业尚无产品实现商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023021018053482b5a7d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023021018053482b5a7d5&s=b","is_publish_highlight":false},{"id":"2310120696","title":"海创药业HP530S片拟用于实体瘤临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2310120696","media":"中国证券网","top":-1,"share":"https://www.laohu8.com/m/news/2310120696?lang=zh_CN&edition=full","pubTime":"2023-02-10 11:06","pubTimestamp":1675998381,"startTime":"0","endTime":"0","summary":"上证报中国证券网讯 海创药业2月9日晚披露，公司近日收到国家药品监督管理局核准签发的《受理通知书》，HP530S片拟用于实体瘤的境内生产药品注册临床试验申请获得受理。目前实体瘤的治疗方案中，存在治疗后肿瘤耐药、免疫逃逸及安全性的风险。随着恶性肿瘤的发病率及死亡率逐年上升，尤其是实体肿瘤，其相关的临床治疗需求将随之增加。HP530S具有和多种药物联合治疗实体瘤的潜力，目前国内外暂无该靶点药物上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230210110816825a867d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230210110816825a867d&s=b","is_publish_highlight":false}],"profile":{"ret":0,"listingDate":"2022-04-12","address":"四川省成都市武侯区高新区科园南路5号蓉药大厦1栋4层附2、3号","stockEarnings":[{"period":"1week","weight":-0.0583},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.5151},{"period":"6month","weight":0.7464},{"period":"1year","weight":0.287},{"period":"ytd","weight":0.37}],"companyName":"海创药业股份有限公司","boardCode":"AI0027","perCapita":"4705股","boardName":"医药制造业","registeredCapital":"9901万元","compareEarnings":[{"period":"1week","weight":-0.0032},{"period":"1month","weight":-0.0067},{"period":"3month","weight":0.0512},{"period":"6month","weight":0.0671},{"period":"1year","weight":0.0096},{"period":"ytd","weight":0.0505}],"survey":" 海创药业股份有限公司是一家基于氘代技术和PROTAC靶向蛋白降解等技术平台，以开发具有重大临床需求的Best-in-class（同类最佳）、First-in-class（国际首创）药物为目标的国际化创新药企业。公司的主要产品为肿瘤、代谢性疾病药品。公司在肿瘤和代谢性疾病领域重点布局，重点搭建了氘代药物研发平台、PROTAC靶向蛋白降解技术平台、靶向药物发现与验证平台与先导化合物优化筛选平台，形成了较强的研发优势和丰富的技术储备。","serverTime":1680040225622,"listedPrice":42.92,"stockholders":"5051人(较上一季度减少15.83%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.12.1","shortVersion":"4.12.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海创药业,688302,海创药业股票,海创药业股票老虎,海创药业股票老虎国际,海创药业行情,海创药业股票行情,海创药业股价,海创药业股市,海创药业股票价格,海创药业股票交易,海创药业股票购买,海创药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海创药业(688302)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海创药业(688302)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}